$16.59
+0.91 (+5.80%)
Open$17.19
Previous Close$15.68
Day High$18.07
Day Low$15.92
52W High$18.43
52W Low$3.22
Volume—
Avg Volume696.0K
Market Cap509.01M
P/E Ratio—
EPS$-1.18
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
+108.6% upside
Current
$16.59
$16.59
Target
$34.61
$34.61
$23.82
$34.61 avg
$34.97
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 78.86M | 61.77M | 25.19M |
| Net Income | -53,505,623 | -37,721,338 | -2,467,246 |
| Profit Margin | -67.9% | -64.5% | -9.8% |
| EBITDA | -44,255,124 | -32,933,078 | -4,050,890 |
| Free Cash Flow | — | — | -1,532,934 |
| Rev Growth | +27.7% | +27.7% | +20.8% |
| Debt/Equity | 9.39 | 9.39 | 0.40 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $295.03 | +0.20% | 50.3 | 520.47B |
| AMGN | Amgen Inc | $465.67 | -0.30% | 26.9 | 252.64B |
| GILD | Gilead Sciences Inc | $168.08 | +0.08% | — | 208.95B |
| VRTX | Vertex Pharmaceuticals Inc | $538.60 | -0.74% | 33.9 | 134.82B |
| REGN | Regeneron Pharmaceuticals | $955.47 | +0.45% | 20.4 | 98.38B |
| ALNY | Alnylam Pharmaceuticals Inc | $165.04 | +5.36% | 7.7 | 20.98B |